Immuno-PET imaging of CD30-positive lymphoma using 89Zr-desferrioxamine-labeled CD30-specific ac-10 antibody

Journal of Nuclear Medicine

Volumn 57, Issue 1, 2016, Pages 96-102

  Rylova, Svetlana N ^a,b   Del Pozzo, Luigi ^a,b   Klingeberg, Cathrin ^a,b   Tönnesmann, Roswitha ^b   Illert, Anna L ^a,b   Meyer, Philipp T ^a,b   Maecke, Helmut R ^b   Holland, Jason P ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

89Zr; Antibody; Brentuximab vedotin; CD30; Lymphoma; PET CT

Indexed keywords

CD30 ANTIGEN; DESFERRIOXAMINE LABELED CD30 SPECIFIC AC 10 ANTIBODY ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; DEFEROXAMINE; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BAGG ALBINO MOUSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG CONJUGATION; DRUG DISTRIBUTION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; PET SCANNER; PRIORITY JOURNAL; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DRUG STABILITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD30; CELL LINE, TUMOR; DEFEROXAMINE; DRUG STABILITY; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOISOTOPES; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84958616550     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.115.162735     Document Type: Article

References (32)

1. Kaudewitz P, Stein H, Burg G, Mason DY, Braun-Falco O. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1. J Invest Dermatol. 1986;86:350-354.
2. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157-164.
3. Dürkop H, Foss H-D, Eitelbach F, et al. Expression of the CD30 antigen in nonlymphoid tissues and cells. J Pathol. 2000;190:613-618.
4. Muta H, Podack E. CD30: from basic research to cancer therapy. Immunol Res. 2013;57:151-158.
5. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62:3736-3742.
6. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3:209-225.
7. van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4:458-465.
8. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190-2196.
9. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183-2189.
10. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236-1243.
11. Moskowitz AJ. New frontiers for brentuximab vedotin for lymphomas. Leuk Lymphoma. 2015;56:283-284.
12. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853-1862.
13. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394-1402.
14. Blum KA. CD30: seeing is not always believing. Blood. 2015;125:1358-1359.
15. Zeng Z, Parekh P, Li Z, Shi ZZ, Tung CH, Zu Y. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics. 2014;4: 945-952.
16. 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors [abstract]. Cancer Res. 2014;74:104.
17. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
18. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
19. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
20. 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
21. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
22. Kim JS, Lee JS, Im KC, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527-1535.
23. 89Zralbumin as a model system. J Nucl Med. 2011;52:625-633.
24. 89Zr-DFO-trastuzumab. PLoS One. 2010;5:e8859.
25. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093-2105.
26. 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191: 1439-1445.
27. 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
28. 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVPAUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20:3945-3954.
29. Gallamini A, Borra A. Role of PET in lymphoma. Curr Treat Options Oncol. 2014;15:248-261.
30. Suresh T, Lee LX, Joshi J, et al. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7:58.
31. Knox SJ. Levy R. CCR 20th anniversary commentary: radioactive drones for B-cell lymphoma. Clin Cancer Res. 2015;21:493-494.
32. Natarajan A, Habte F, Gambhir SS. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem. 2012;23:1221-1229.